Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.8.9389.1992
Address
QQ Block, Nedlands 6 Verdun Street QEII Medical Centre Perth, Western Australia (WA) 6009
Description
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company was founded by Richard Lipscombe and Bill Parker in 2001 and is headquartered in Perth, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.77 - 1.4
Trade Value (12mth)
AU$42,213.00
1 week
6.67%
1 month
2.33%
YTD
-5.38%
1 year
3.53%
All time high
1.48
EPS 3 yr Growth
80.40%
EBITDA Margin
-916.60%
Operating Cashflow
-$6m
Free Cash Flow Return
-62.00%
ROIC
-70.70%
Interest Coverage
-352.80
Quick Ratio
10.10
Shares on Issue (Fully Dilluted)
131m
HALO Sector
Healthcare
Next Company Report Date
02-Sep-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.06
Date | Announcements |
---|---|
27 August 24 |
Notification of cessation of securities - PIQ
×
Notification of cessation of securities - PIQ |
23 August 24 |
Preliminary Final Report
×
Preliminary Final Report |
23 August 24 |
Corporate Governance Statement and Appendix 4G
×
Corporate Governance Statement and Appendix 4G |
23 August 24 |
Annual Report to shareholders
×
Annual Report to shareholders |
23 August 24 |
Groundbreaking results for type 1 diabetes and kidney health
×
Groundbreaking results for type 1 diabetes and kidney health |
12 August 24 |
Resignation of Director and Appendix 3Z
×
Resignation of Director and Appendix 3Z |
30 July 24 |
June 2024 Quarterly Activities Report and Appendix 4C
×
June 2024 Quarterly Activities Report and Appendix 4C |
12 July 24 |
Notification of cessation of securities - PIQ
×
Notification of cessation of securities - PIQ |
08 July 24 |
Application for quotation of securities - PIQ
×
Application for quotation of securities - PIQ |
24 June 24 |
Eurobio Scientific to sell PromarkerD DKD test in France
×
Eurobio Scientific to sell PromarkerD DKD test in France |
20 June 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
17 June 24 |
Proteomics appoints medical devices sales agency for Europe
×
Proteomics appoints medical devices sales agency for Europe |
17 June 24 |
Issue of Equity Incentives to Employees
×
Issue of Equity Incentives to Employees |
17 June 24 |
Notification regarding unquoted securities - PIQ
×
Notification regarding unquoted securities - PIQ |
27 May 24 |
Change of auditor entity
×
Change of auditor entity |
16 May 24 |
Promarker technology used for diagnosing plant dieback
×
Promarker technology used for diagnosing plant dieback |
17 April 24 |
March 2024 Quarterly Activities Report and Appendix 4C
×
March 2024 Quarterly Activities Report and Appendix 4C |
28 March 24 |
Investor presentation
×
Investor presentation |
25 March 24 |
Proteomics signs with Oxford Univ to validate test for Endo
×
Proteomics signs with Oxford Univ to validate test for Endo |
18 March 24 |
PromarkerD US commercialisation & Promarker pipeline update
×
PromarkerD US commercialisation & Promarker pipeline update |
06 March 24 |
Proteomics International retains its ISO13485 certification
×
Proteomics International retains its ISO13485 certification |
28 February 24 |
European patent granted for OxiDx technology
×
European patent granted for OxiDx technology |
23 February 24 |
Interim Financial Report and Appendix 4D
×
Interim Financial Report and Appendix 4D |
06 February 24 |
Investor presentation - Euroz Hartleys Healthcare Forum
×
Investor presentation - Euroz Hartleys Healthcare Forum |
01 February 24 |
Study validates biomarkers for oesophageal cancer blood test
×
Study validates biomarkers for oesophageal cancer blood test |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.